by Wenlong Carl Chen, The Conversation Credit: Unsplash/CC0 Public Domain A breakthrough study has identified the genetic risk factors that contribute to increased prostate cancer in African men. The study, the largest of its kind, recruited 7,500 men from eastern, southern and west Africa. The study is especially important because African men have a high risk...
Category: <span>Research Updates</span>
Post
New research reveals two types of fatty liver disease
by Karolinska Institutet Putative model of the two different types of MASLD. Credit: Nature Medicine (2024). DOI: 10.1038/s41591-024-03284-0 Researchers at Karolinska Institutet and the University of Gothenburg have identified two types of metabolic-associated fatty liver disease—a liver-specific type and a systemic type that affects other organs and tissues. The discovery could lead to improved diagnosis and treatment of...
Post
Stomach cancer can be caused by a bacterium carried by half the people on Earth, but screening for it isn’t easy
by Delthia Ricks , Medical Xpress Credit: Pixabay/CC0 Public Domain In 1982, two Australian physician–scientists discovered a spiral-shaped bacterium whose form not only dictated its function, but its capacity to dwell in the human body’s harshest chemical environment would help identify it as the cause of serious afflictions of the stomach, including cancer. Drs. Barry...
Post
Neuron-based research model helps decode rare neurological disease
by Tel-Aviv University Differential effects of TIMM50 mutation on the expression of TIM23, PAM and TOM subunits and matrix-destined proteins. Credit: eLife (2024). DOI: 10.7554/eLife.99914.2 Researchers at Tel Aviv University have developed an innovative research model that allowed them to decode the mechanism underlying a severe and rare neurological disease. The disease is characterized by symptoms such as...
Post
MASH discovery redefines subtypes with distinct risks: shaping the future of fatty liver disease treatment
Peer-Reviewed Publication INSERM (Institut national de la santé et de la recherche médicale) Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), impacts roughly 30% of the global adult population. The disease spans from benign fat accumulation in the liver (steatosis) to its more severe form, metabolic dysfunction-associated steatohepatitis...
Post
Study links high-fiber diet to delayed progression of blood cancer
by Memorial Sloan Kettering Cancer Center Credit: Unsplash/CC0 Public Domain Researchers at Memorial Sloan Kettering Cancer Center (MSK) have reported results from the first-ever clinical trial demonstrating that a high-fiber, plant-based dietary intervention may delay progression to multiple myeloma, a rare and incurable blood cancer affecting the bone marrow. The study enrolled 20 participants with a precancerous blood...
Post
New AI stroke brain scan readings are twice as accurate as current method
by Samantha Rey06 December 2024 view large AI pinpoints stroke timing, treatment potential from a single scan New AI software can read the brain scans of patients who have had a stroke, to more accurately pinpoint when it happened and help doctors work out whether it can be successfully treated. It is hoped that the new...
Post
Neuroscientists discover a new pathway to forming long-term memories in the brain
by Max Planck Florida Institute for Neuroscience Scientists discover a new pathway to long-term memory formation in the brain that can bypass the formation of short-term memory. Credit: Helena Pinheiro Researchers from Max Planck Florida Institute for Neuroscience have discovered a new pathway to forming long-term memories in the brain. Their work, published in Nature Neuroscience, suggests that long-term...
Post
Repurposed drug has promising efficacy in non-small cell lung cancer
by UT Southwestern Medical Center UT Southwestern researchers (l-r) Farjana Fattah, Ph.D., Mitchell S. von Itzstein, M.D., David E. Gerber, M.D., and Kelly Kyle, B.S., discovered a drug that shows promise in treating non-small cell lung cancer with KRAS mutations. Credit: UT Southwestern Medical Center An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in...
Post
LBCL: Bispecific Antibodies Fare Less Well in Real-World Analysis
Randy Dotinga December 07, 2024 01 SAN DIEGO — Compared with clinical trials, a real-world retrospective analysis has linked the bispecific antibodies epcoritamab (Epkinly) and glofitamab (Columvi) to somewhat poorer outcomes in relapsed or refractory large B-cell lymphoma (LBCL). In a presentation here at the American Society of Hematology (ASH) 2024 Annual Meeting, researchers reported that of 172 patients treated with the...